Page 123 - Read Online

Kornberg et al. Hepatoma Res 2018;4:60 I http://dx.doi.org/10.20517/2394-5079.2018.86 Page 15 of 19

Hepatol 2017;2:63.
29. El-Fattah MA. Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA. Indian J Gastroenterol
2017;36:117-25.
30. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner
E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular
carcinoma: a prospective validation study. Hepatology 2016;64:2077-88.
31. Andreou A, Bahra M, Guel S, Struecker B, Sauer IM, Klein F, Pascher A, Pratschke J, Seehofer D. Tumor DNA index and α-fetoprotein
level define outcome following liver transplantation for advanced hepatocellular carcinoma. Eur Surg Res 2015;55:302-18.
32. Kim SH, Moon DB, Kim WJ, Kang WH, Kwon JH, Jwa EK, Cho HD, Ha SM, Chung YK, Lee SG. Preoperative prognostic values of
α-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for
living donor liver transplantation. Hepatobiliary Surg Nutr 2016;5:461-9.
33. Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, Balsanek JG, Ward MM, Giama NH,
Moser CD, Oseini AM, Umeda N, Venkatesh S, Harnois DM, Charlton MR, Yamada H, Satomura S, Algeciras-Schimnich A, Snyder MR,
Therneau TM, Roberts LR. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver
transplantation. Liver Transpl 2015;21:599-606.
34. Cescon M, Bertuzzo VR, Ercolani G, Ravaioli M, Odaldi F, Pinna AD. Liver transplantation for hepatocellular carcinoma: role of
inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol 2013;19:9174-82.
35. Hsu CC, Chen CL, Wang CC, Lin CC, Yong CC, Wang SH, Liu YW, Lin TL, Lee WF, Lin YH, Chan YC, Wu YJ, Eng HL, Cheng YF.
Combination of FDG-PET and UCSF criteria for predicting HCC recurrence after living donor liver transplantation. Transplantation
2016;100:1925-32.
36. Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H. Patients with non-[18 F]fludeoxyglucose-avid
advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. Liver
Transpl 2012;18:53-61.
37. Chapman WC, Garcia-Aroz S, Vachharajani N, Fowler K, Saad N, Lin Y, Wellen J, Tan B, Khan AS, Doyle MB. Liver transplantation for
advanced hepatocellular carcinoma after downstaging without up-front stage restrictions. J Am Coll Surg 2017;224:610-21.
38. Agopian VG, Morshedi MM, McWilliams J, Harlander-Locke MP, Markovic D, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Hiatt JR,
Busuttil RW. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver
transplantation: analysis of 501 consecutively treated patients. Ann Surg 2015;262:536-45.
39. Fernandes JV, Cobucci RN, Jatobá CA, Fernandes TA, de Azevedo JW, de Araújo JM. The role of the mediators of inflammation in cancer
development. Pathol Oncol Res 2015;21:527-34.
40. Horiguchi H, Loftus TJ, Hawkins RB, Raymond SL, Stortz JA, Hollen MK, Weiss BP, Miller ES, Bihorac A, Larson SD, Mohr AM,
Brakenridge SC, Tsujimoto H, Ueno H, Moore FA, Moldawer LL, Efron PA; Sepsis and Critical Illness Research Center Investigators.
Innate immunity in the persistent inflammation, immunosuppression, and catabolism syndrome and its implications for therapy. Front
Immunol 2018;9:595.
41. Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol
2018;2:6.
42. Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol
2018;19:222-32.
43. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1.
44. Toso C, Mentha G, Majno P. Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant
2011;11:2031-5.
45. Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, Yoshizumi T, Abe K, Aishima S, Maehara Y. New scoring system for
prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int 2014;34:937-41.
46. Sun C, Liao W, Deng Z, Li E, Feng Q, Lei J, Yuan R, Zou S, Mao Y, Shao J, Wu L, Zhang C. The diagnostic value of assays for circulating
tumor cells in hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2017;96:e7513.
47. Noor MT, Manoria P. Immune dysfunction in cirrhosis. J Clin Transl Hepatol 2017;5:50-8.
48. Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME, Hiotis SP. Impact of liver
fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer 2013;109:573-81.
49. Sasaki K, Shindoh J, Margonis GA, Nishioka Y, Andreatos N, Sekine A, Hashimoto M, Pawlik TM. Effect of background liver cirrhosis on
outcomes of hepatectomy for hepatocellular carcinoma. JAMA Surg 2017;152:e165059.
50. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and
predictors of survival. Gastroenterology 2008;134:1342-51.
51. Halazun K, Przybyszewski E, Verna E, Samstein B, Fox A, Brown R, Emond J. The influence of rising Lab MELD on vascular invasion in
HCC. Available from: https://atcmeetingabstracts.com/abstract/the-influence-of-rising-lab-meld-on-vascular-invasion-in-hcc/. [Last accessed
on 26 Sep 2018]
52. Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting
outcome in 1074 patients in OPTN Region 5. Clin Transplant 2015;29:506-12.
53. Komorowski AL, Hsu CC, Julka KD, Vasavada B, Lin CC, Wang CC, Chen CL. AFP role in predicting recurrence of hepatocellular
carcinoma after living donor liver transplantation in HCV patients. Neoplasma 2018;65:455-60.
54. Foerster F, Mittler J, Darstein F, Heise M, Marquardt JU, Wörns MA, Weinmann A, Sälter L, Hoppe-Lotichius M, Heinrich S, Kloeckner
R, Pitton MB, Schattenberg JM, Sprinzl MF, Düber C, Otto G, Lang H, Galle PR, Zimmermann T. Recipient liver function before liver
transplantation influences post-transplantation survival in patients with HCC. Eur J Intern Med 2018;55:57-65.
55. Faitot F, Allard MA, Pittau G, Ciacio O, Adam R, Castaing D, Cunha AS, Pelletier G, Cherqui D, Samuel D, Vibert E. Impact of clinically